Treatment of patients with CLOVES (a PIK3CA-related overgrowth syndrome) with the PIK3CA inhibitor BYL719P leads to improved symptoms with a decrease in the size of their VAs, and improved cardiovascular measures such as congestive heart failure, cardiac hemihypertrophy, and scoliosis (115). Here, PIK3CA is linked to congestive heart failure.